On October 24, 2022 Enosi Therapeutics, a drug research and development company focused on providing industry-leading therapeutics for cancer and autoimmune diseases, reported that Enosi CEO and CSO, Dr. H. Michael Shepard, will be presenting the company’s preclinical work in a presentation titled "High affinity ligand traps derived from the EGFR and HER3 are efficacious in murine models of cancer and autoimmune disease" at the ENA 2022 Symposium being held in Barcelona October 26-28, 2022 (Press release, Enosi Therapeutics, OCT 24, 2022, View Source [SID1234622327]). ENA is a joint program of the National Cancer Institute, the American Association of Cancer Research and the European Organization for Research and Treatment of Cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ENA 2022 is a drug development and translational research meeting, focusing on presentations and discussions regarding preclinical and phase I studies, drawing some of the foremost experts in the field from around the world. The symposium enables in-depth scientific discussions on the latest drug developments and attracts academics, scientists, and pharmaceutical industry executives to discuss the latest innovations in drug research and development.
EN-2642 is an affinity matured EGFR-Fc: HER3:Fc ligand trap and binds 9 of the 11 growth factors which activate the HER family. These growth factors participate in the progression of many diseases, including solid cancers and rheumatoid arthritis, which are characterized by hyperproliferative cells, hypoxia, angiogenesis, and inflammation.
"This therapeutic strategy is unique because it does not depend upon antibodies binding the cell surface, resulting in total signaling blockade or antibody-mediated cellular toxicity, but rather on starving diseased cells which are dependent upon an excess of free growth factors. The problem with earlier "Pan-HER" approaches has been that in most cases the targeted receptors are not overexpressed and thus toxicity results to non-diseased tissues," said Dr. Shepard.
Enosi’s poster will be presented on the opening day of the conference, "Molecular Targeted Agents 1" on Wednesday, October 26, 2022.